GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Asset Turnover

NRXS (Neuraxis) Asset Turnover : 0.34 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Neuraxis's Revenue for the three months ended in Jun. 2024 was $0.61 Mil. Neuraxis's Total Assets for the quarter that ended in Jun. 2024 was $1.79 Mil. Therefore, Neuraxis's Asset Turnover for the quarter that ended in Jun. 2024 was 0.34.

Asset Turnover is linked to ROE % through Du Pont Formula. Neuraxis's annualized ROE % for the quarter that ended in Jun. 2024 was 276.52%. It is also linked to ROA % through Du Pont Formula. Neuraxis's annualized ROA % for the quarter that ended in Jun. 2024 was -652.25%.


Neuraxis Asset Turnover Historical Data

The historical data trend for Neuraxis's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Asset Turnover Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Asset Turnover
0.69 1.53 2.40 2.47

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.34 0.61 0.89 0.34

Competitive Comparison of Neuraxis's Asset Turnover

For the Biotechnology subindustry, Neuraxis's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuraxis's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Neuraxis's Asset Turnover falls into.



Neuraxis Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Neuraxis's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=2.46/( (1.481+0.509)/ 2 )
=2.46/0.995
=2.47

Neuraxis's Asset Turnover for the quarter that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=0.612/( (0.946+2.633)/ 2 )
=0.612/1.7895
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Neuraxis  (AMEX:NRXS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Neuraxis's annulized ROE % for the quarter that ended in Jun. 2024 is

ROE %**(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-11.672/-4.221
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-11.672 / 2.448)*(2.448 / 1.7895)*(1.7895/ -4.221)
=Net Margin %*Asset Turnover*Equity Multiplier
=-476.8 %*1.368*-0.424
=ROA %*Equity Multiplier
=-652.25 %*-0.424
=276.52 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Neuraxis's annulized ROA % for the quarter that ended in Jun. 2024 is

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=-11.672/1.7895
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-11.672 / 2.448)*(2.448 / 1.7895)
=Net Margin %*Asset Turnover
=-476.8 %*1.368
=-652.25 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Neuraxis Asset Turnover Related Terms

Thank you for viewing the detailed overview of Neuraxis's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuraxis Business Description

Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042